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Abstract
In the central nervous system (CNS), activation of the transcription factor nuclear factor-
kappa B (NF-κβ) is associated with both neuronal survival and increased vulnerability to
apoptosis. The mechanisms underlying these dichotomous effects are attributed to the
composition of NF-κΒ dimers. In Alzheimer’s disease (AD), β-amyloid (Aβ) and other
aggregates upregulate activation of p65:p50 dimers in CNS cells and enhance transactiva-
tion of pathological mediators that cause neuroinflammation and neurodegeneration.
Hence selective targeting of activated p65 is an attractive therapeutic strategy for AD. Here
we report the design, structural and functional characterization of peptide analogs of a p65
interacting protein, the glucocorticoid induced leucine zipper (GILZ). By virtue of binding
the transactivation domain of p65 exposed after release from the inhibitory IκΒ proteins in
activated cells, the GILZ analogs can act as highly selective inhibitors of activated p65 with
minimal potential for off-target effects.
1. Introduction
An accumulating body of evidence suggests that a combination of age related changes in the
central nervous system (CNS) with excessive or prolonged inflammatory responses contribute
to the pathophysiology of neurodegeneration, synaptic dysfunction and hippocampal behavior
deficits in conditions such as Alzheimer's disease (AD) [1, 2]. The pleiotropic transcription fac-
tor, nuclear factor-kappa B (NF-κΒ) is induced by many physiological and pathological stimuli
in the CNS [2–4]. The NF-κΒ family consists of five members, p50, c-rel, p65, RelB and p52
that can diversely combine to form transcriptionally active dimers. It has been suggested that
the nature of the dimers determine the effects of activated NF-κΒ. While c-rel containing
dimers preferentially promote transactivation of anti-apoptotic factors, activation of p65/p50
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dimers primarily enhance inflammatory and pro-apoptotic gene transcription. Positive and
negative regulatorymechanisms maintain a balance between the neuroprotective c-rel dimers
and the predominantly deleterious p65:p50 dimers in healthy CNS [2, 5, 6].
In AD, secondary stimuli such as accumulating beta amyloid (Aβ) and oxidative stress
increase activation of p65:p50 dimers in glial cells [7]. Cleavage of amyloid precursor protein
(APP) by beta site amyloid precursor protein cleaving enzyme-1 (BACE-1) is essential for Aβ
generation. The promoter region of human BACE-1 gene exhibits κΒ binding elements that
physically interact with NF-κΒ p65 [8, 9]. Activation of NF-κΒ p65 increases endogenous BACE-
1 transcription and consequent Aβ production [8, 10]. Increased presence of activated p65 and
BACE-1 has been observedaround Aβ plaques in postmortemAD tissues [11–13]. Extracellular
Aβpeptides predominantly activate p65:p50 dimers in glia and post-mitotic neurons and enhance
transactivation of inflammatory and pro-apoptotic genes [13–15]. Increased presence of IL-1β,
IL-6, and TNF-α have been reported in the affected tissues, serum and CSF of AD patients [16,
17]. Elevated Bax (proapoptotic) to Bcl-2 (anti-apoptotic) ratio have been observed in Aβ stimu-
lated neuronal cells [18, 19]. A feed-back loop of excessive Aβ accumulation, NF-κΒ activation,
cytotoxicity and more Aβ production culminate in neurodegeneration [20]. Conditional knock
out of p65 has been shown to attenuate BACE-1 transcription and Aβ genesis in ADmice [10].
Absence of p65 co-factors such as p300/CREB binding associated factor has been shown to medi-
ate resistance to Aβ induced toxicity [21]. Thus, although neuronal p65 has been shown to con-
tribute to the physiological functions of synapse formation and transmission, considerable
evidence suggest that excessive activated p65 in the CNS lead to neurodegenerative pathology.
Hence selective inhibition of activated p65 could suppress AD [2, 16].
Structurally p65 has an amino terminal rel homology domain (RHD), a nuclear localization
sequence (NLS) masked by the κΒ inhibitory complex and a carboxy terminal transactivation
domain (TAD). The transactivation activity of p65 is mediated by interactions of the TAD
with co-regulators and the basal transcriptionmachinery [22, 23]. Glucocorticoid induced leu-
cine zipper (GILZ) is a p65 binding protein that sequesters activated p65 and inhibits transacti-
vation of inflammatory and apoptotic factors [24, 25]. Mutational and binding analyses
localized the interaction interface to the proline rich carboxy terminus of GILZ and the TAD of
p65 [26]. Molecular modeling suggested that the p65 binding domain of GILZ adopts a flexible
polyproline type II (PPII) helical conformation that interacts with the highly conservedF534/
F542 in p65-TAD [27].
In recent years, considerable success has been achieved in the development of structurally
engineered peptide analogs of the binding epitope(s) of a protein as therapeutic leads [28, 29].
The strategy is increasingly adopted in the design of mimics of proline rich motif that mediate
transient intermolecular interactions. The specificity of the interaction is determined by the
nature of the proline rich binding domain interface [30, 31]. Here we investigated the efficacy
of rationally designed peptide analogs of the p65-TAD binding region of GILZ to selectively
sequester activated p65. Structural and functional analyses suggest that select GILZ analog
(GA) bind p65-TAD with optimum affinity, exhibit an estimated half minimal lethal dose
comparable to known peptide drugs and suppress Aβ1–42 induced cytotoxicity.
2. Materials and Methods
Peptides and reagents
All GILZ peptides were synthesized as peptide amides with amino-terminal acetylation (Gene-
script, Piscataway, NJ) at 95% purity as confirmedby mass spectrometry. To facilitate intracellular
delivery the GA were either co-synthesizedwith the cell penetrating agent, TAT (transactivator of
transcription) peptide or used as covalent mixture with Pep-1 chariot peptide (Anaspec, Fremont,
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CA). Recombinant human p65 protein (r-p65) with DDK tag (catalog number TP320780), puri-
fied recombinant human GILZ protein (r-GILZ) with GST tag and biotinylated anti-DDK anti-
bodywere fromOri-GeneTechnologies Inc., Rockville,MD. PurifiedAβ1–42 peptidewas
purchased fromAmerican Peptide company (American peptide company, Sunnyvale, CA: Prod-
uct # 62-0-80 Lot # 1310160T). Aβ1–42 peptide stock (1 mg/mL) was prepared in cell culture
medium and incubated at 37°C for 24h prior to use in cell cultures [32].
Comparative modeling
Models of human GILZ and its mimics were built by the CPHmodels and Geno3D servers
using delta sleep inducing peptide (DSIP-PDB:1DIP) as template based on> 90% sequence
similarity[33].While the Geno3D system builds models based on ‘topology mapping, the CPH
system uses profile-based alignment as seed for developing energy-minimizedhomology
model [34, 35]. The secondary structure assignment of the GILZmodels was independently
assessed by the PROSS (Protein dihedral angle-based Secondary Structure assignment) pro-
gram[36]. Superimposition of the model of each GILZmimic with experimentally determined
PPII helix and wild type GILZ determined the similarity between the structures in terms of root
mean square deviation (RMSD). Homology models of p65-TAD was developed similarly using
elongation factor eEF3 (PDB:3H7H) as template with which it shares 42% sequence similarity
[37].
GILZ:p65-TAD docking
Models of human GILZ or GILZmimic and the p65-TAD were applied as probe and target
respectively in PatchDock, a geometry based algorithm that yields docked transformations
scored on the basis of molecular shape complementarity and atomic desolvation energy [38–
40]. Top one thousand solutions were refined using FireDock (Fast Interaction Refinement in
molecular docking), a program that optimizes binding of the probe by restricting side-chain
flexibility to clashing interface residues. The refined docking solutions were scored based on
softened van derWaals interactions, atomic contact energy, electrostatic and additional bind-
ing free energy estimations. The top ranked solutions so obtained were further screened using
Chimera for interatomic distance of<5Å between the residues of GILZmimic and the func-
tionally critical residues of p65-TAD [41]. The solution with most contacts was further refined
by FlexPepDock using the wild type GILZ:p65-TAD complex with greater than 50% intermo-
lecular residue contacts as reference.
Binding of GILZ and human r-p65
Previously we observed that the r-GILZ exhibits ten times higher affinity than a 22 residue
GILZ peptide for r-p65 [27]. We used similar method to determine direct binding kinetics of
GA hexapeptides with human r-p65. High binding ELISA plates were coated with increasing
concentrations of r-GILZ (0.5μM to 20μM) or each GA or control peptide (20μM-640μM) and
probed with 80μM r-p65 followed by detectionwith anti-DDK antibody. Absorbance at 650nm
was measured with a mixing time of 30s using BIORADmicroplate reader. Percent bound p65
was determined considering the binding response of r-GILZ (20μM) with r-p65 as 100%. The
dissociation constant of the interaction between the GA or the control peptide and r-p65 was
determined by the method of Friguet et al., as described [42, 43]. A fraction of the bound r-p65
(x) and the ratio of bound r-p65 to the free GA or control peptide (y) was determined by the
equations: x = (Ao − A)/(Ao), where Ao is the absorbance of r-p65anti-p65 complex in the
absence of bound GA or control peptide and y = (Ao−A/Ao)/(ao− io)×(Ao − A/Ao), where ao is
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the total concentration of GA or control peptide and io is the total concentration of r-p65. KD
for the interaction was determined by the Scatchard equation: x = 1 + KD/y.
Cell Titer-Glo (CTG) luminescent cell viability assay
Human neuroblastoma (SK-N-SH) cells cultured in minimal essential medium (MEM) supple-
mented with 1% fetal bovine serum (FBS) and 1% penicillin (100U/ml)/streptomycin (100μg/
ml) were differentiated with 10 μM all-trans retinoic acid for 7 days [32, 44]. After resting for
24h in the low serummedium, the cells were seeded in 24 well (105cells/well) culture plates in
fresh medium and incubated with 50μM or 500μM of individual GA or control peptide in non-
covalent mixture with Pep-1 or Pep-1 alone for additional 24h. The cultures were then photo-
graphed using a phase contrast Leicamicroscope (LeicaMicrosystems Inc, Buffalogrove, IL).
Subsequently, the cells were harvested, lysed with lysis buffer (M-PER, Pierce) and the lysate
was assessed for metabolic activity using the luciferase based CTG assay (CTG, Promega,
Madison,WI). Briefly, cell lysate (5μL) in 25μL of phosphate buffered saline was transferred to
an opaque white 96-well plate, and then 30μL of CTG assay solution was added. The relative
luminescent signal (RLT) was quantified using a Glowmax luminometer (Promega).
Lactate dehydrogenase (LDH) assay
To detect direct GA-induced cell lysis we performed LDH release assays (RocheMolecular
Diagnostics).Human glioblastoma (U373) cells were maintained in MEM supplemented with
10% FBS and 1% penicillin (100U/ml)/streptomycin (100μg/ml) at 37°C in 5% CO2-humidified
incubators and sub-cultured once or twice a week [32, 45]. Approximately 5 x 104 U373 cells/
well were cultured in 96-well plates in the presence of increasing concentrations of individual
GA or control peptide from 0.5μM to 500μM. Cells treated with 2% triton-X 100 (Sigma
Aldrich, St. Luis, MO) for 10 minutes served as positive control. Untreated cells served as con-
trols for spontaneous LDH-release. Specific LDH-release was calculated according to the fol-
lowing formula: LDH-release % = 100×(GA or control peptide treated cells—untreated cells)/
(positive control-untreated cells). The IC50 values were extrapolated by logarithmic estimation.
The LD50 in mg/kg was predicted using the formula, Log (LD50) = 0.435x (log IC50) + 0.625
[46].
Detection of apoptosis by flow cytometry
To further assess cell cytotoxicity, the apoptotic effects of individual GA or control peptide was
evaluated by the Annexin-V and propidium iodide (PI) dual staining method (Annexin-
V-Fluos staining kit, Roche Diagnositics,Mannheim, Germany) [47]. As opposed to apoptotic
cells, necrotic cells with ruptured cell membrane take up PI, the DNA binding dye. Thus, cells
which take up both fluorochromes are a mixture of apoptotic and necrotic cells, whereas cells
that exclude PI but bind Annexin V are (early) apoptotic cells. U373 cells cultured with varying
concentrations of individual GA or control peptide (0.5μM to 50μM) for 24h were centrifuged
and suspended in 100μl of Annexin V/PI labelling solution (20μl each of Annexin-V-Fluos
labelling reagent and PI in 1ml of binding buffer) for 15min at room temperature. After wash-
ing the cells were resuspended in PBS:1% paraformaldehyde and analyzed using a FACScan
flow cytometer (BD Biosciences, San Jose, CA).
Functional assays in human primary mixed brain cultures (HFB)
HFBwere prepared and cultured as described [48] (S1 and S2 Docs). Briefly, cells were cultured
in Neurobasal medium (Invitrogen) without phenol red supplemented with 1xB27, 50mM
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GlutaMAX, 1xantibiotic cocktail, 5ng/mL recombinant fibroblast growth factor 2 (bFGF)
(Invitrogen), and 2μL/mLNormocin (InVivoGen, San Diego, CA, USA). Cells were counted
and seeded onto poly-D-lysine (Sigma-Aldrich) coated 24-well plates (Corning, Lowell, MA,
USA) at 1.5x105 cells per well and maintained at 37°C in a 5% CO2 incubator. Half media
changes were performed every 4th day of culture and morphologywas monitored via phase
contrast microscopy. Culture mediumwas removed from cells on day 17 (DIV17) and replaced
with Neurobasal mediumwith B27. Appropriate wells were then added vehicle, or individual
GA or control peptide (at 40μM or highest LD50 concentration) covalently synthesized with
TAT or carrier peptide alone for 30min followed by exposure to Aβ1–42 at a final concentration
of 10μM/ well and incubated for 4h or 48h. Cells and conditionedmedia were harvested and
stored for further analysis. Relative ATP concentration was measured using the CTG kit (Pro-
mega) [45]. Data is presented as ΔRLU = RLU of Aβ1–42 exposed cells–RLU unexposed cells.
Conditionedmedia collectedwere assessed for specific cytokines using the OptEIA kits (BD
Biosciences).
NF-κΒ assay
PrimaryHFB exposed to Aβ1–42 and treated with GA or CP as above was harvested at the end
of 4h. Nuclear and cytoplasmic fractions were extracted using the CelLytic™ NuCLEAR™
ExtractionKit (Sigma) followingmanufacturer’s protocol. Five microgram of nuclear extracts
was incubated in a 96-well plate coated with oligonucleotides containing the NF-κΒ consensus
nucleotide sequence (5’-GGGACTTTCC-3’).The activated NF-κΒ bound to DNA was
detected by anti-p65 antibody followed by a peroxidase coupled secondary antibody and sub-
strate using the TransAM kit protocol (Active Motif).Nuclear extracts of Raji cells was used as
the positive control [49].
Quantitative real-time polymerase chain reaction (RT-PCR)
PrimaryHFB exposed to Aβ1–42 and treated with GA or CP as above was harvested at the end
of 24h. Total cellular RNA was isolated using Qiagen kit (Invitrogen, Carlsbad, CA) following
manufacturer's protocol. Total RNA (2–4 μg) was reverse transcribedusing iScript cDNA syn-
thesis kit (Biorad, CA). The concentration of the cDNA was measured at 260 and 280 nm by
the Gensys5 model UV-visible spectrophotometer (ThermoelectronicCorp.,CA). Real-time
PCR was performed by using the SYBR green/ROX qPCRmaster mix (SABiosciences, Freder-
ick, MD) according to manufacturer's recommendations on the CFX96 Touch™ Real-Time
PCRDetection System (Biorad laboratories, Hercules, California, USA). Each reaction contains
2×12.5 μl of SYBR greenMaster Mix, 1 μl of 10 μM of primers and 50 ng of the cDNA, to a
total volume of 25 μl. The thermal cycling conditions included an initial denaturation step at
50°C for 2 min, 95°C for 3 min, 39 cycles at 95°C for 30 s, annealing temperature at 54°C for
30 s and extension at 72°C for 30s. The primers are F-GAPDH-50-AAGGTGAAGGTCGGA
GTC AAC-30; R-GAPDH:50-G GGGTCATTGATGGCAACAATA-3 0(102bp); F-IL-1β:50-AG
CTG ATGGCCCTAAACAGA-3 0; R-IL-1β:50GGTCGGAGATTCGTAGCTGG-3 0 (89 bp);
F-IL-6:50-AATTCGGTACATCCTCG ACGG-30; R-IL-6:50-CAGCTCTGGCTTGTTCCTCA-
30 (260bp); F-Caspase3:50-CATGGAAG CGAATCAATGGACT -30; R-Caspase 3–50 TTCCCT
GAGGTTTGCTGCAT-30 (165 bp); F-Caspase 9: 50-CACTTCCCCTGAAGACGAGTC-30 and
R-Caspase 9: 50-CTGATGTGCTCACCTGGGAAA-30 (162 bp). The gene-specific threshold
cycle (Ct) for each sample (ΔCt) was corrected by subtracting the Ct for the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Untreated controls were chosen as the
reference samples, and the ΔCt for all experimental samples was subtracted by the ΔCt for the
control samples (ΔΔCt). The difference in each gene-specific threshold between the samples
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from vehicle treated and GA or CP treated cells was determined to obtain the relative change
in the specificmRNA. The magnitude of change in the mRNA was expressed as 2ΔΔCt. Each
measurement of a sample was conducted in duplicate.
Statistical analysis
Statistical significancewas assessed by one-way analysis of variance (ANOVA) followed by
Tuckey post hoc. A value of p< 0.05 was considered significant.
3. Results
Design and modeling of GILZ mimic
Strategies to determine the smallest biologically active fragment of a lead peptide involves trun-
cation, deletion, alanine scanning and substitution of residues[29]. Deletion studies suggested
that the amino terminal helix of GILZ is critical for dimerization but is not involved in the
interaction with NF-κΒ. Truncation mutants suggested that the residues spanning 120P-P127 of
the GILZwere critical for GILZmediated inhibition of NF-κΒ transactivation [24, 26]. Molecu-
lar modeling showed that the GILZ-COOHor a 22 residue peptide derived from the proline
rich region adopted an extended PPII helical conformation and interacted with the p65-TAD
exhibiting weak binding kinetics [27]. Alanine scanningmutagenesis suggested that the substi-
tution of the 120PXXP123 motif abrogated the ability to inhibit NF-κΒ transactivation poten-
tially due to loss of PPII conformation[24, 25]. In human and mouse GILZ, hydrogen bonding
between the side chain of Ser or Thr and the backbone carbonyl of Glu or Pro respectively
could contribute to the stability of PPII conformation [50]. We designed 40 GILZmimics by
incorporating rational substitutions in the p65 binding motif of GILZ with residues that
increase the propensity for PPII helical conformation and stabilize it. Comparative modeling
with substituted residues for all 40 GA was performed to obtain structural representation of
each with reference to the adjacent residues of human GILZ. In addition we introduced confor-
mational constraints by superimposing each GILZmimic model on structures with solved or
experimental PPII helix and wild type human GILZ to select for mimics with significant struc-
tural homology (Fig 1). The PPII content of GILZmimics as determined by PROSS ranged
from 14.3%, 28.6% and 42.9%. Since PPII helix formation is a locally driven event with little/no
involvement of long-range interactions [51, 52], it is logical to presume that the synthetic GILZ
mimetic peptide with blocked end groups will adopt a similar conformation as in the predicted
model. Twenty GILZmimics that exhibit near structural congruencewith DSIP (<1Å) or wild
type GILZ or experimentally determined PPII structure (<2Å) were selected for in silico
docking.
Docking of GILZ mimic and p65-TAD
To be of potential therapeutic value, the GILZmimic should adopt PPII helical conformation
in the context of the critical binding residues in p65-TAD. The p65-TAD is commonly divided
into two distinct regions, TAD-1521−551 consisting of 36 amino acids and TAD-2428−520 with 92
residues [23]. It has been reported that the TAD1 accounts for nearly 95% of the transactivation
potential of full-length p65 and that the TAD2 alone is less potent mediating about 30% activa-
tion [22, 53]. In particular, the highly conserved aromatic residues (F534, F542), acidic residues
(D531,D533) and phosphorylation sites (Ser529,Ser536) in p65-TAD1 have been identified as criti-
cal for transactivation [54].
Homology model of p65-TAD was built using solution structure of the elongation factor
eEF3 (PDB: 2XI3, 2WI3) with which it shares 42% sequence similarity[37]. The spatial
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orientations of wild type GILZ and top 20 GILZmimics with p65-TAD were assessed by multi-
ple docking algorithms. One thousand interaction possibilities identified by rigid-docking
algorithmwere improved by coarse refinement to restrict side-chain flexibility at the interface.
The docked complexes were ranked using an optimized global energy function for higher prob-
ability prediction. Top ten solutions of each GILZmimic were evaluated for proximity to
p65-TAD residues. In general two residues are considered in contact with each other if the dis-
tance between the Cβ atoms is<5Å [55]. Interactions between the conservedF534/F542 in the
p65-TAD1 and the critical prolines P120/P123 of GILZ could promote C–Hπ interaction and
provide substantial binding energy in the GILZ:p65-TAD complex. All solutions that exhibited
an RMSD of<5Å with the critical F534 and F542 were selected for further screening (Table 1).
Sixty of the top one hundred predictions of wild type GILZ exhibited close proximity with
nearly 50% of p65-TAD1 residues suggesting near-native interactions (Fig 2A). The wild type
GILZ:p65-TAD complex with the lowest global energy and maximum contacts with p65-TAD
was selected as reference for refining each of the 20 GILZmimic-p65TAD complexes in
two hundred independent FlexPepDock simulations. Significantly ten of the twenty GILZ
mimics exhibited interatomic distance of<5Å not only with the conservedphenylalanine in
p65-TAD1 but also with the putative LXXLLmotif in p65-TAD2 (Fig 2B and 2C). The LXXLL
motif commonly observed in transcription factors are known to mediate protein–protein
Fig 1. Comparative modeling of GILZ analogs: Superimposition of human delta sleep inducing peptide (DSIP; PDB: 1DIP) with the predicted model of
human GILZ (A), superimposition of indicated analog (blue) with the critical residues in the proline glutamic acid rich region of human GILZ model (red)
(B-F). Structural similarity in terms of root mean square deviation (RMSD) for each superimposition is indicated.
doi:10.1371/journal.pone.0160314.g001
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interactions [56]. A rank order was developed based on percent PPII content, structural similar-
ity with wild type GILZ and percent contact with p65-TAD. We selected two GILZmimics or
analogs (GA-1 and GA-2) that exhibit near native docking, structural congruencewith experi-
mental PPII and wild type GILZ and good PPII potential for screening by cellular analyses. In
addition we selected one mimic with good PPII potential but fewer contacts with p65-TAD and
two GILZmimics that possess low PPII content but acceptable percent contact with the
p65-TAD in docking analyses as control peptides for PPII conformation (control peptide 1)
and p65 docking potential (control peptide 2 and control peptide 3) respectively.
Kinetics of GA:-p65 interaction
Previously the strength of interaction between rGILZ or wild type GILZ-P and r-p65 has
been shown to be 5.91±2.4×10−7M and 1.12 ± 0.25×10−6M respectively[27].We evaluated the
binding kinetics of individual GA at increasing concentrations with the plate bound r-p65 pro-
tein at constant concentration.We observed that the percent bound r-p65 was over 25% with
GA-1, GA-2 and CP-1 even at the lowest concentration evaluated (Fig 3A). The dissociate
constant, KD, as calculated by the method of Friguet et al. was 2.29+/-0.2x10-6M for GA-1 and
Table 1. Characteristics of twenty GILZ mimics.
Superimposition p65-Transactivation Domain
% PPII PPII GILZ model % TA1 %TA-2
CR-1 CR-2 CR-3
521–531 435–455 462–479 491–505
GA-1 14.3 0.82 0.216 19 43 39 20
GA-2 42.9 0.531 0.216 18 32 13 9
GA-3 14.3 0.109 0.428 11 14 23 4
GA-4 14.3 1.049 0.482 4 13 47 29
GA-5 28.6 1.234 0.586 11 14 23 4
GA-6 14.3 0.844 0.645 21 54 34 9
GA-7 14.3 0.156 0.681 30 20 0 11
GA-8 14.3 1.72 0.842 15 41 32 5
GA-9 42.9 0.257 0.88 24 42 29 13
GA-10 28.6 0.161 0.9 12 38 23 7
GA-11 28.6 0.703 0.912 20 46 23 6
GA-12 42.9 1.17 1 10 12 18 6
GA-13 14.3 0.58 1.018 3 35 55 6
GA-14 28.6 1.172 1.033 32 28 10 2
GA-15 14.3 0.391 1.047 12 36 8 7
GA-16 14.3 0.252 1.154 18 38 33 1
GA-17 28.6 1.293 1.227 15 25 24 9
GA-18 14.3 1,248 1.243 16 24 31 22
GA-19 28.6 0.581 1.49 7 22 24 7
GA-20 42.9 1.174 1.613 37 43 9 2
GILZ models (GM) with substituted residues at the proline rich region of wild type GILZ sequence were
developed using Geno3D and CPH Models. Each GA model was superimposed over wild type GILZ and
experimentally determined polyproline (PPII) helical structures. The root mean square deviation (RMSD) of
each superimposition as a measure of structural similarity is shown. Each GM was docked with the
molecular model of p65-TAD and the docked complexes were screened for interface p65-TAD residues
within 5Å distance of GM.
doi:10.1371/journal.pone.0160314.t001
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3.24+/-0.19x10-6M for GA-2. The strength of interaction of the GA:p65-TAD binding is con-
sistent with other transient protein:peptide interactions such as that of peptide inhibitors of
matrix metalloproteinase and that of SMRT peptides binding the BTB domain of BCL6 [57,
58]. The control peptides exhibited higher KD values of 3.27+/-1.8x10-6M, 3.4+/-0.15x10-6M
and 4.28+/-0.5 x10-6M for CP-1, CP-2 and CP-3 respectively (Fig 3B–3F).
Effect of GA on cellular morphology and metabolic activity
Any compound with potential therapeutic effect should be biocompatible and nontoxic. So, we
first screened the effects of GA on cellular morphology and viability. Cultures of neuroblasts
exposed to 50μM or 500μM of individual GA or CP-1 or CP-2 did not show any change in cell
morphology suggesting that the four peptides were not toxic. Exposure to CP-3 at either con-
centration showed morphological changes consistent with cell death (Fig 4A). The effect of GA
on cellular metabolic activity was assessed by the CTG assay which measures intracellular ATP
concentrations as an indicator of actual cell number. The results of the CTG assay were very
similar and showed that the two GA and CP-1 and CP-2 did not adversely affect the differenti-
ated neuroblastoma cells, but treatment with CP-3 reduced the viability of the cells at both con-
centrations tested (Fig 4B).
Fig 2. The docked complex of wild type GILZ-PER (proline glutamic acid rich region) or GILZ analog (GA) with human p65-TAD. Representative
molecular model of p65-TAD docked (blue) with wild type GILZ-PER (A) and indicated analog (B-F) (red) are shown. The residues in each analog <5Å
distance of highly conserved residues in p65-TAD2 (Phe or Phe) and the “LXXLL” motif in p65-TAD1 that suggest proximity with residues critical for
transcriptional activity are shown.
doi:10.1371/journal.pone.0160314.g002
Inflammation, Neurodegeneration and NF-κB
PLOS ONE | DOI:10.1371/journal.pone.0160314 October 20, 2016 9 / 22
Effect of GA on membrane integrity and apoptosis
Membrane integrity as a measure of cell survival was assessed by the leakage of intracellular
LDHmolecules into culture medium [44]. Treatment with GA-1 and GA-2 were best tolerated
as indicated by the reduced% LDH release at all concentrations as compared to untreated cul-
tures or cultures exposed to control peptides (Fig 5A). IC50 extrapolated from regression analy-
sis is 226.78 μM for GA-1 and 198.4 μM for GA-2 (Fig 5C and 5D). The IC50 was lower for
CP-1 (49.9 μM), CP-2 (26.58 μM) and CP-3 (26.63 μM) (Fig 5E–5G). Using the Speilmann
method, the LD50 in mg/kg body weight is estimated to be 19.78 for GA-1 and 18.66 for GA-2
and 10.2, 7.78 and 7.79 for CP-1, CP-2 and CP-3 respectively [46]. Many therapeutic peptides
such as leuprolide and glatiramer acetate have been shown to exhibit similar LD50 values[59,
60]. Furthermore the cytotoxic effect of each peptide at increasing concentration from 0.5μM
to 50μM was assessed by Annexin and PI staining (Fig 5B). GA-1 and GA-2 exhibit< 25%
apoptosis at highest concentration.
Select GA protects against Aβ1–42 induced toxicity in human fetal brain
cells (HFB)
We used an in-vitro neurodegenerationmodel in which primary human fetal brain cells are
allowed to mature gradually. The system provides an opportunity to test the pharmacological
Fig 3. GA-rp65 binding analysis: Binding between the plate-bound GILZ analog (GA) or control peptide (CP) (20μM-640μM) at increasing
concentration and the r-p65 was detected with the anti-DDK as described in the methods section. A dose dependent decrease in percent bound r-
p65 was observed in association with the GA (A). Data represent average+/-SD from three experiments. Scatchard plot analysis of bound p65 (A0-A/A0)
against the ratio of bound p65 to free GA (y = (Ao-A/Ao)/[(Ao-A/Ao)* (ao-io)] was used to determine the dissociation constant for the interaction between
indicated GA and r-p65 (B-F).
doi:10.1371/journal.pone.0160314.g003
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Fig 4. Effect of GILZ analog (GA) on cellular morphology and metabolic activity in neuroblasts:
Differentiated SK-N-SH neuroblastoma cultures were exposed to individual GA or control peptide (CP) at
the indicated concentration for 24h. (A) Phase contrast imaging of the cells shows no apparent adverse effects
on morphology of cells exposed to GA-1 or GA-2 or CP-1 or CP-2 at either concentration. Exposure to CP-3 at
both concentrations showed morphological changes consistent with cell death. (B) Cell lysates were assessed by
CTG assay to determine relative levels of intracellular ATP. An increase in Relative Luminescence Units (RLU)
suggesting cellular viability was observed with all treatments except CP-3. Data represent average+/-SD from
three experiments.
doi:10.1371/journal.pone.0160314.g004
Inflammation, Neurodegeneration and NF-κB
PLOS ONE | DOI:10.1371/journal.pone.0160314 October 20, 2016 11 / 22
and toxicological effects of GA on differentiated neurons and glia simultaneously[48]. The rela-
tive ATP concentration of GA or control peptide treated HFB cultures in the presence or
absence of Aβ1–42 over the cultures exposed to vehicle alone (Δ-RLU) was determined by the
CTG assay. Cultures exposed to GA were best tolerated while the cultures treated with CP-2 or
CP-3 exhibited significant toxicity (Fig 6A). The mean RLU of vehicle treated cells varied
between 7352.75+/-1265.2 and 16157.5+/-4950 and the average RLU of cultures exposed to
Aβ1–42 varied between 6067.25+/-903.05 and 11574.25+/- 4139.3 in different experiments. The
viability was significantly higher in cells exposed to Aβ1–42 and treated with GA-1 or GA-2 (Fig
6B). Although Δ-RLU was higher in cultures treated with CP-1, it was not significant when
compared to that in untreated Aβ1–42 exposed cultures. The relative concentration of IL-1β was
Fig 5. Effect of GA on lactate dehydrogenase (LDH) release: U373 MG astroglioma cells were exposed to
increasing concentrations of indicated GILZ analog (GA) or control peptide (CP) (0.5μM to 1mM) for 24 h.
The release of LDH into the cell culture supernatant from damaged cells was measured. % LDH was calculated as
the ratio of the difference between the peptide treated and untreated cells to that of the difference between the
positive control and the untreated cells (A). Data represent average +/- SD from three experiments. The IC50 was
determined by logarithmic extrapolation (C-G). Flow cytometric analysis of Annexin positive U373 cells treated as
indicated was determined as a measure of apoptosis (B).
doi:10.1371/journal.pone.0160314.g005
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lower in culture medium of cells exposed to Aβ1–42 and GA-1 (16.4 +/-3.3pg/ml) or GA-2 (30.5
+/-7.9 pg/ml) treated cells as compared with control peptide treated (CP-1:21.7+/-5.03pg/ml,
CP-2: 42.1+/-1.3pg/ml,CP-3: 47.8+/-4.4pg/ml) or untreated (36.1+/-5.6pg/ml) cells. Similarly
IL-6 and IL-12 secretion was lower in GA-1 (0.9+/-1.4pg/ml and 61.6+/-32.2pg/ml respec-
tively) or GA-2 (18.4+/-0.1pg/ml and 104.5+/-24.8pg/ml respectively) treated cells as com-
pared with CP-1 (19.17+/-12.2pg/ml and 125.7+/-46.3pg/ml respectively), CP-2 (38.6+/-10.2
pg/ml and 149.9+/-50.7pg/ml respectively), CP-3 (39.2+/-11.7pg/ml and 239.9+/-19.4pg/ml
Fig 6. Effect of GILZ analog (GA) treatment on human fetal brain cells (HFB): (A,B): Select GA decrease metabolic activity in Aβ1–42
exposed HFB. Primary cultures of HFB (Div 17) were exposed to Aβ1–42 and treated with 50M of indicated GA or control peptide (CP).
Cytoplasmic extracts of cells collected at 24h was assessed for viability by CTG assay. Data are presented as ΔRLU (difference in relative
luminescent units (RLU) between the Aβ1–42 exposed cells and unexposed cells) (A, B). GA suppresses inflammatory cytokines in activated
HFB. HFB cells were cultured as above and culture medium collected at 24hrs was assessed for pro-inflammatory (IL-1β, IL-6 and IL-17) (C,
D, E and F) and anti-inflammatory (TGF-β) (G) cytokines. (H) Effect of GA on NF-κΒ activation. Primary cultures of HFB exposed to Aβ1–42
(10μg/ml) and treated with indicated GA or CP as above were harvested at the end of 4 h. 5μg of nuclear extract was tested for binding of the
activated p65 NF-κΒ subunit to an NF-κΒ consensus sequence using the Trans AM NF-κΒ ELISA kit. The p65 DNA binding activity was
calculated as the ratio of absorbance from Aβ1–42 stimulated cells to that of unstimulated cells. Values are the average/-S.D from two
experiments. * = p<0.05 as compared to Aβ1–42 exposed cells, @ = p<0.05 as compared with Aβ1–42 and CP-1 or CP-2 treated cultures.
doi:10.1371/journal.pone.0160314.g006
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respectively) treated or untreated (10.7+/-1.5pg/ml and 104.5+/-24.8pg/ml respectively) cells
(Fig 6C–6E). The relative concentration of IL-17 did not differ between cells treated with GA-1
(8.3+/- 1pg/ml) or GA-2 (9.4+/-0.01pg/ml) peptide and control peptide (CP-1:11.4+/-1.6pg/
ml, CP-2: 6.5+/-1.2pg/ml and CP-3: 16.7+/-2 pg/ml) or untreated cells (10 +/-0.6 pg/ml) (Fig
6F). The relative concentration of TGF-β was significantly upregulated in cells treated with
GA-1 (46.9+/-5.4pg/ml) or GA-2 (67.1+/-10.2pg/ml) as compared with untreated cells (21.7
+/-0.7pg/ml). The relative concentration of TGF-βmeasured 39.2+/-0.7pg/ml, 32.9+/-7.3pg/
ml and 33.9+/-5.6pg/ml in CP-1, CP-2 and CP-3 treated cells respectively (Fig 6G). Further
exposure to Aβ1–42 resulted in upregulation of mRNA for IL-1β and IL-6. The relative expres-
sion (fold increase) of IL-1β and IL-6 mRNA was reduced in cells treated with GA-1 (2.5
+/-0.23 and 2.9+/-1 respectively) or GA-2 (6.9+/-1.4 and 4+/-4.5 respectively) as compared
with CP-1 (8.2+/-1.7 and 12.9+/-1.2 respectively), CP-2 (14.4+/-4.6 and 8.2+/-1.7 respectively)
CP-3 (12.6+/-1.5 and 7.2+/-0.6 respectively) or untreated (16.4+/-2 and 6.3+/-1.5 respectively)
cells (Fig 7A–7C).
Select GA treatment inhibits activated p65
Previously Aβ1–42 has been shown to enhance expression of activated NF-κΒ in glia and post-
mitotic neurons [14, 15]. We measured nuclear p65 using activated NF-κΒ specific ELISA and
calculated the p65 DNA binding activity as the ratio of absorbance form Aβ1–42 stimulated cells
Fig 7. Effect of GILZ analog (GA) treatment on apoptosis related molecules in human fetal brain cells: Primary cultures of
HFB were exposed to Aβ1–42 and treated with 50μM of indicated GA or control peptide (CP). Total RNA was isolated from cells
harvested after 24h and assessed for mRNA for IL-1β, IL-6, Caspase-3 and Caspase-9 by quantitative PCR. The mRNA expression in
each sample was finally determined after correction with GAPDH expression. (A) Gel electrophoresis of the PCR products GAPDH
(111bp), IL-1β (89bp), IL-6 (260bp), Caspase-3 (165bp) and Caspase-9 (162bp). (B) Relative mRNA quantitation of IL-1β (B), IL-6 (C),
Caspase-3 (D) and Caspase-9 (E) with respect to that of housekeeping gene GAPDH is shown. Data are average of two experiments
and expressed as means ±SD. * = p<0.05 with respect to vehicle treated cells.
doi:10.1371/journal.pone.0160314.g007
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to that of unstimulated cells. Nuclear p65 was significantly higher in cells exposed to Aβ1–42
(14.75+/-3.5) than in unexposed cells (2.5+/-1.7). There was a trend towards decreasednuclear
p65 in Aβ1–42 exposed cells treated with GA-1 (6.13+/-1.3) and GA-2 (6.7+/-1.5) as compared to
untreated cells (14.75+/-3.5). Nuclear p65 of Aβ1–42 exposed cells treated with CP-1, CP-2 and
CP-3 measured 6.8+/-3.9, 10.2+/-2.9 and 10.1+/-3.7 respectively (Fig 6H). No significant differ-
ence in nuclear p65 was observed in cells treated only with the peptides in the absence of expo-
sure to Aβ1–42 (data not shown). Similar assessment showed no significant difference in the
cytoplasmicNF-κΒ p65 betweenGA treated and untreated or CP treated cells (data not shown).
Although we observed slightly elevated nuclear p50 in Aβ1–42 (6.15+/-1.2) than in unexposed
cells (0.5+/-2.7), no differencewas observedbetweenGA peptide of CP treated cells and
untreated cells (data not shown).
Select GA protects against Aβ1–42 induced apoptosis related markers in
human fetal brain cells (HFB)
We next determined the message for apoptosis relevant molecules Caspase 3 and Caspase 9 by
quantitative PCR. As shown in Fig 7, exposure to Aβ1–42 resulted in upregulation of mRNA for
caspase 3 and caspase 9 in HFB. The relative expression (fold increase) of IL-1β and caspase 9
mRNA was reduced in cells treated with GA-1 (2.5+/-0.23 and 1.3+/-0.9 respectively) or GA-2
(6.9+/-1.4 and 1.3+/-1 respectively) as compared with CP-1 (8.2+/-1.7 and 6.5 +/-2.2 respec-
tively), CP-2 (14.4+/-4.6 and 7.1+/-4.5 respectively) CP-3 (12.6+/-1.5 and 12.8+/-2.8 respec-
tively) or untreated (16.4+/-2 and 2.9+/-0.7 respectively) cells (Fig 7A, 7B and 7E). Further the
IL-6 and Caspase 3 mRNA exhibited significant reduction in GA-1 (2.9+/-1 and 1.7+/-0.3
respectively) treated cells as compared to that in CP-1 (12.9+/-1.2 and 17.7+/-1.5 respectively)
treated or untreated (6.3+/-1.5 and 5.8+/-0.9 respectively) cells (Fig 7A, 7C and 7D).
Comparative analysis of physical and functional characteristics of known receptor antago-
nists and peptide drugs in clinical use today with that of GA, suggest that the GA-1 and GA-2
exhibit significant drug like properties (Table 2).
4. Discussion
There is increasing interest in developing diseasemodifying agents for neurodegenerative dis-
eases based on molecular pathogenesis. Increased NF-κΒ p65 secondary to aging and environ-
mental stimuli contribute significantly to the inflammation and degeneration in AD [1, 2, 16].
Synthetic compounds including terpenoids like adenanthin and resveratrol or other sirtuin
activators interact with NF-κΒ p65, suppress inflammation and cytotoxicity in ADmodels
Table 2. Physical and functional characteristics of GILZ analog and control peptides.
Structural similarity
RMSD
Docking features %PPII # rotatable
bonds
Log P KD (μM) LD50 (mM) %
apoptosis
Overall rank
WT GILZ PPII
peptide
%TA-1 %TA-2 >25 <25 <10 >10 <5 >5 <3 >3 >100 <100 <25 >25
<1 >1 <1 >1 >25 <25 >25 <25
1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0
GA-1 1 1 1 0 0 1 1 1 1 1 8
GA-2 1 1 1 0 1 1 1 0 0 1 7
CP-1 1 0 1 0 1 0 1 0 1 1 6
CP-2 0 0 1 1 1 0 0 0 0 1 4
CP-3 0 0 1 0 1 1 0 0 0 3
doi:10.1371/journal.pone.0160314.t002
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[61]. As opposed to high throughput screening, computational design of interface peptide
mimics followed by functional evaluation represents an efficientmethod in the drug design
and discovery process [28, 29]. Here we report the design and physicochemical characteristics
of peptide analogs of the GILZ:p65 interface, show that select analogs bind p65-TAD and sup-
press Aβ induced toxicity in human fetal brain cells exhibiting potential therapeutic value for
AD.
In human interactome, preponderant transient intermolecular interactions are mediated by
proline rich epitope of one protein binding the aromatic residue rich flat interface of the second
protein. Often the proline rich epitope adopts an extended PPII helical conformation that behaves
as an adaptable glove in obtaining the correct binding orientation [31, 52]. Here it is pertinent to
note that the template basedmodeling suggested that the p65 binding domain of GILZ exhibits a
PPII helical conformation and that the p65-TAD is unstructured or flat. Mutational analyses
identified 120PEA(S)P124 of GILZ as hot spot residues for interacting with NF-κΒ p65[24, 26]. In
the GILZ:p65-TAD complex, the critical proline of GILZ, 120P exhibits φ and ψ angles of -67° ±5°
of 142.5° ± 15° respectively and is in close proximity with the conservedphenylalanines (534F,
542F) of p65-TAD. Collectively, these observations suggest that the GILZ:p65-TAD complex rep-
resents a druggable target for development of specific therapeutic leads.
Incorporating rational substitutions in the polyproline motif of GILZ in the context of the
p65-TAD interface we designedmultiple peptide analogs of GILZ or GA.Molecular superposi-
tion is one of the most important means to interpret the relations between three-dimensional
structures. The low RMSD upon superimpositionwith experimental PPII and wild type GILZ
suggests that the select GA represent true structuralmimic of the p65 binding domain of GILZ.
Significantly docking analyses showed that the top ranked GA exhibited>20% contact with
the functionally critical p65-TAD residues (F534, F542) in>90% of docked solutions.
An important advantage of proline-rich motif at interface of transient intermolecular inter-
actions is the weak binding kinetics without compromising affinity. Furthermore, it allows for
introduction of small changes in the sequence of the motif or its binding domain to mediate
large changes in the affinity of the interaction [31, 62, 63]. We observed that the GA-1 and GA-
2 exhibited greater affinity for binding r-p65 than the full length r-GILZ. Previously, proline
rich peptides that bind Src homology 3 binding domain or the transcription factor human
estrogen receptor alpha or the cell surface CD80 ligand have been shown to exhibit dissociation
constant (KD) in the micromolar range and inhibit protein:protein interactions [64, 65].
Functionally, GA-1 and GA-2 inhibitedmetabolic activity and suppressed cytokine
responses in activated human brain cells suggesting a protective potential against Aβ induced
pathology. Further we observed that GA-1 significantly suppressed caspase-3 and caspase-9
transcripts in Aβ induced human brain cells. Considerable evidence suggests that the caspases
play active role in Aβ1–42 induced neurotoxicity. Multiple caspases including caspase-3 and cas-
pase-9 are transcriptionally elevated in AD [66, 67]. Caspase-3 has been shown to cleave APP,
thereby enhancing Aβ plaque formation and toxicity. In AD transgenic mouse model that
overexpress human mutant APP, Aβ accumulation has been shown to lead to aberrant cas-
pase-3 activation triggering a cascade of down-stream signaling events leading to synaptic loss
and behavioral changes [67, 68]. Caspase-9 has been shown to induce apoptosis by directly
cleaving APP or indirectly by triggering caspase-3 cleavage in AD [66, 69]. Many of the NF-κΒ
antagonists including peroxisome proliferator-activated receptor-gamma agonists and anti-
oxidants such as melatonin have been shown to suppress Aβ-induced caspase-3 activity [70,
71]. Collectively, the ability to suppress Aβ induced inflammatory and cytotoxic responses in
human fetal brain cells support therapeutic potential for GA-1 and GA-2 in AD.
Many peptide drugs including copaxone, leuprolide acetate/goserelin (peptide antagonists
of GnRH receptor), octreotide (a cyclic octapeptidemimicking natural hormone somatostatin)
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and glucagon like peptide-1(GLP-1) analog have been evaluated in models of AD substantiat-
ing the credibility of peptide drugs for AD [59, 60, 66]. Proline rich PPII helical peptides such
as apidaecin, oncocin and drosocin have shown to exhibit significant influx into CNS and dis-
tribution within the brain parenchyma [67]. Hence PGA is likely to cross the blood brain
Fig 8. Schematic representation of pathological mechanisms of AD and points of intervention by GA: Increased oxidative stress
and other age related changes upregulate NF-κΒ p65 which in turn increase transcription of beta site amyloid precursor protein
cleaving enzyme-1 (BACE-1) leading to generation and accumulation of Aβ peptides in the CNS parenchyma. Glial cells exposed to
Aβ peptides exhibit increased p65 activation and secrete inflammatory and apoptosis mediators. Affected neurons upregulate Aβ peptides
and the vicious cycle of Aβ deposition, inflammation and neuronal apoptosis leads to AD. GILZ analogs (GA) by virtue of binding activated
NF-κΒ p65 blocks Aβ generation and suppressing inflammation, thereby ameliorating AD pathology.
doi:10.1371/journal.pone.0160314.g008
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barrier and reach optimal concentration in the brain to be clinically efficient. Significantly, the
estimated LD50 for GA-1 and GA-2 as determined by the method of Speilmann et al. is within
the range of these peptide drugs [46]. Furthermore the ability of GA-1 and GA-2 to suppress
Aβ induced inflammatory and cytotoxic responses in human fetal brain cells suggests potential
as AD therapeutic agents.
5. Conclusion
The goal of biological therapies is to restore healthy balance by targeting specificmolecules
that are critical for mediating or perpetuating imbalanced cellular responses. In recent years
peptide-baseddrugs have gained considerable value in the discovery phase of drug develop-
ment, in particular in the design of interface mimotopes [28, 29]. The functionally active pep-
tides are amenable to furthermodifications into peptidomimetic compounds or small
molecules with improved pharmacokinetic properties. In this context, the low molecular
weight GA-1 and GA-2 can act as lead compounds in the development of specific small mole-
cule inhibitors of NF-κΒ p65 with significant therapeutic potential for chronic neurodegenera-
tive diseases including AD (Fig 8). Since the GA peptides exhibit similar hydrophobicity,
hydropathicity, hydrophilicty and amphipathicity, the cellular uptake is likely to be equivalent.
Evaluation of in-vivo stability and pharmacokinetics will be included in futures studies.
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